Olympus Corp
TSE:7733
Net Margin
Olympus Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Olympus Corp
TSE:7733
|
2.3T JPY |
9%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
226.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
146.4B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.7B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.5B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.3B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.7B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
285.3B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.6B USD |
10%
|
Olympus Corp
Glance View
Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Olympus Corp's most recent financial statements, the company has Net Margin of 8.5%.
You don't have any saved screeners yet